---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-096483"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2026-08-14T12:10:29+00:00"
generated_at: "2026-08-14T12:15:11.634202+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Replimune wins FDA accelerated approval for TUDRIQEV melanoma combo; Q1 net loss $69.8M

## Summary
- FDA granted accelerated approval for TUDRIQEV (RP1) plus nivolumab in advanced melanoma; launch within 60 days.
- Completed $150M financing; net proceeds $141M; cash and equivalents $195.3M as of June 30, 2026.
- Q1 FY2027 net loss $69.8M vs $86.7M; R&D $49.3M, SG&A $19.0M.
- Michelle DiNapoli appointed Chief Commercial Officer, effective Aug 18, 2026; ex-Deciphera.
- IGNYTE-3 confirmatory trial readout expected 2030; REVEAL Phase 2/3 for RP2 enrolling.

## SEC filing metadata
- accession: 0001104659-26-096483
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2026-08-14T12:10:29+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465926096483/0001104659-26-096483-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465926096483/tm2623208d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-096483
- JSON: https://secwatch.observer/filing/0001104659-26-096483.json
- Plain text: https://secwatch.observer/filing/0001104659-26-096483.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.